News

We recently supported a customer where the scale of production made it impossible to replicate the process beforehand in a traditional lab setting.

We recently completed this lab skid featuring SpinPro R2 flow reactor technology. With this GMP-compatible lab skid, our customer can develop, validate and scale their emulsification processes directly on site, under conditions that reflect real production.

We recently completed a proof-of-concept demonstration with our partner, Pi-Process Internsification Experts LLP in India, for a slurry-forming process, using our SpinPro Flow Reactor.

Flowid will participate as a Gold Sponsor at Flow Chemistry India 2026, taking place on September 10 - 11 in Hyderabad, India. During this flow chemistry conference, we will show how complex and hazardous chemical processes can be turned into safe, scalable and reliable continuous production.

In our latest article "Accelerating mixing-limited processes with Spinning Disc Reactors" you will explore the power of Spinning Disc Reactors, such as our own SpinPro, and how they are unlocking new levels of efficiency, safety and performance in chemical processing.

Flowid is excited to join 𝗖𝗵𝗲𝗺𝗣𝗿𝗼𝗧𝗲𝗰𝗵 𝗜𝗻𝗱𝗶𝗮 𝟮𝟬𝟮𝟲 together with our partner R&D Therm (I) Pvt Ltd. The exhibition will be held on April 29th and 30th in Bombay Exhibition Centre, Mumbai. You will find us at stand 3A06 in hall 8.

Proud to present our newest custom-designed pharma production skid, powered by our SpinPro R3 dynamic reactor technology. The goal? Enable our customer to scale up emulsification capacity while achieving the highest level of process control and product consistency. 

We are proud to announce the establishment of Flowid India Private Limited, marking a significant milestone in our mission to accelerate the global adoption of flow chemistry.

One of the most expensive steps in many API processes is converting the API into its HCl salt form, which is crucial for bioavailability, but traditionally slow, costly, and inefficient in batch. Flowid helps API manufacturers by making essential steps in drug production more cost-effective.